Miruvor
Sign up
The short answer

What studies of Specialized pro-resolving mediators (SPM Active) found

4papers on Specialized pro-resolving mediators (SPM Active)
192people in 2 studies testing Specialized pro-resolving mediators (SPM Active) alone
2randomised trials, the strongest kind of study

At a glance, by condition

Long COVID: C Might help, very uncertain

Based on the strongest evidence, the randomised trial and studies with no comparison group and the placebo trial (very low certainty): 3 of 6 findings are C, a tie, so the grade of daily functioning, as the rule below says.

5 outcomes rated · see each below

How we got this

Each condition’s headline comes from its graded findings (one for each outcome and kind of study) rated with the highest certainty: the grade most of them share; a tie goes to the finding with the most people, then the most studies, then the outcome’s name. It sums up the grades below, and conditions are never combined.

What this means: Specialized pro-resolving mediators (SPM Active) might help some people with long COVID, but research can’t show it yet. If you’re thinking about it, talk it through with a doctor who knows ME/CFS or long COVID.

Ask about this treatment

Sign up free to read the rest of what studies found.

You’ll see the full picture: how each symptom fared, every grade with its reasons, side effects, the doses studied and all 4 papers.

The grades, in plain words

Each outcome gets a direction, a certainty and a letter read from the two. Certainty is judged with GRADE, the method Cochrane and WHO use.

  1. A
    HelpsImprovement, high certainty
    Probably helpsImprovement, moderate certainty
  2. B
    May helpImprovement, low certainty
  3. Specialized pro-resolving mediators (SPM Active) · Long COVID is hereC
    Might help, very uncertainImprovement, very low certainty
    Mixed resultsStudies disagree
  4. D
    Little or no differenceStudies found little or no difference
  5. F
    HarmsIt made things worse

By symptom and daily life

Long COVID

Symptoms

Fatigue2 studies · 192 people took Specialized pro-resolving mediators (SPM Active) Little or no difference D
Very low certainty

Why this grade: Little or no difference, very low certainty, from randomised trials: high risk of bias (RoB 2) in the results that carry most of the weight; one trial of 53 people found no clear difference; a small benefit can't be ruled out.

The randomised trial53 randomised · 12 weeks · 3000 mg/day

No clear difference in fatigue.

The evidence is very uncertain about the effect of specialized pro-resolving mediators (SPM Active) on fatigue in long COVID. Little or no difference · very low certainty D

  • High risk of bias (RoB 2) in the results that carry most of the weight
  • One trial of 53 people found no clear difference; a small benefit can't be ruled out

Studies with no comparison group144 randomised · after 12 weeks

Fatigue improved.

The evidence is very uncertain about the effect of specialized pro-resolving mediators (SPM Active) on fatigue in long COVID. Improvement · very low certainty C

  • No control group: part of any change may be placebo, natural recovery or regression to the mean (risk of bias by design)
  • Not all results were tested against chance
See the 2 studies
  1. Pro-resolving Inflammatory Effects of a Marine Oil Enriched in SPMs Supplement and Its Implication in Patients with a Post COVID Syndrome (PCS) (2024)

    People in the study
    53 randomised
    Dose
    3000 mg/day
    Outcome
    Fatigue Severity Scale (FSS) score: differences among the four treatment groups Fatigue Severity Scale
    Effect
    no clear difference
    Risk of bias
    RoB 2: High
    Randomisation process
    Some concerns
    Deviations from intended interventions
    High
    Missing outcome data
    High
    Measurement of the outcome
    High
    Selection of the reported result
    Some concerns
  2. Effects of Specialized Pro-Resolving Mediators and Telerehabilitation on Fatigue, Dyspnea, and Quality of Life in Post‑COVID‑19 Condition: The ARACOV-02 Randomized Controlled Trial. (2026) preprint

    People in the study
    144 randomised
    Dose
    —
    Outcome
    fatigue (FSS) Fatigue severity scale
    Effect
    better (not tested)
    Risk of bias
    before-after study without a control group (JBI checklist for quasi-experimental studies); not rated with RoB 2 or ROBINS-I
Breathlessness1 study · 47 people took Specialized pro-resolving mediators (SPM Active) Little or no difference D
Very low certainty

Why this grade: Little or no difference, very low certainty, from randomised trials: high risk of bias (RoB 2) in the results that carry most of the weight; one trial of 53 people found no clear difference; a small benefit can't be ruled out.

The randomised trial53 randomised · 12 weeks · 3000 mg/day

No clear difference in breathlessness.

The evidence is very uncertain about the effect of specialized pro-resolving mediators (SPM Active) on breathlessness in long COVID. Little or no difference · very low certainty D

  • High risk of bias (RoB 2) in the results that carry most of the weight
  • One trial of 53 people found no clear difference; a small benefit can't be ruled out
See the 1 study
  1. Pro-Resolving Inflammatory Effects of a Marine Oil Enriched in Specialized Pro-Resolving Mediators (SPMs) Supplement and Its Implication in Patients with Post-COVID Syndrome (PCS). (2024)

    Same trial, also reported in: Pro-resolving Inflammatory Effects of a Marine Oil Enriched in SPMs Supplement and Its Implication in Patients with a Post COVID Syndrome (PCS) (2024) (mMRC Dyspnea Scale score: differences among the four treatment groups)

    People in the study
    53 randomised
    Dose
    3000 mg/day
    Outcome
    mMRC Dyspnea Scale (baseline vs week 12 and week 4) Modified Medical Research Council (mMRC) Dyspnea Scale
    Effect
    no clear difference
    Risk of bias
    RoB 2: High
    Randomisation process
    Some concerns
    Deviations from intended interventions
    High
    Missing outcome data
    High
    Measurement of the outcome
    Low
    Selection of the reported result
    Some concerns

Daily life and health overall

Daily functioning1 study · 144 people took Specialized pro-resolving mediators (SPM Active) Improvement C
Very low certainty

Why this grade: Improvement, very low certainty, from studies without a control group: no control group: part of any change may be placebo, natural recovery or regression to the mean (risk of bias by design).

Studies with no comparison group144 randomised · after 12 weeks

Daily functioning improved.

The evidence is very uncertain about the effect of specialized pro-resolving mediators (SPM Active) on daily functioning in long COVID. Improvement · very low certainty C

  • No control group: part of any change may be placebo, natural recovery or regression to the mean (risk of bias by design)
See the 1 study
  1. Effects of Specialized Pro-Resolving Mediators and Telerehabilitation on Fatigue, Dyspnea, and Quality of Life in Post‑COVID‑19 Condition: The ARACOV-02 Randomized Controlled Trial. (2026) preprint

    People in the study
    144 randomised
    Dose
    —
    Outcome
    functional capacity (6MWT) 6-minute walk test
    Effect
    better
    Risk of bias
    before-after study without a control group (JBI checklist for quasi-experimental studies); not rated with RoB 2 or ROBINS-I
Quality of life1 study · 144 people took Specialized pro-resolving mediators (SPM Active) Improvement C
Very low certainty

Why this grade: Improvement, very low certainty, from studies without a control group: no control group: part of any change may be placebo, natural recovery or regression to the mean (risk of bias by design); not all results were tested against chance.

Studies with no comparison group144 randomised · after 12 weeks

Quality of life improved.

The evidence is very uncertain about the effect of specialized pro-resolving mediators (SPM Active) on quality of life in long COVID. Improvement · very low certainty C

  • No control group: part of any change may be placebo, natural recovery or regression to the mean (risk of bias by design)
  • Not all results were tested against chance
See the 1 study
  1. Effects of Specialized Pro-Resolving Mediators and Telerehabilitation on Fatigue, Dyspnea, and Quality of Life in Post‑COVID‑19 Condition: The ARACOV-02 Randomized Controlled Trial. (2026) preprint

    People in the study
    144 randomised
    Dose
    —
    Outcome
    health-related quality of life (EQ‑5D‑5 L)
    Effect
    better (not tested)
    Risk of bias
    before-after study without a control group (JBI checklist for quasi-experimental studies); not rated with RoB 2 or ROBINS-I
Overall symptoms1 study · 144 people took Specialized pro-resolving mediators (SPM Active) Little or no difference D
Very low certainty

Why this grade: Little or no difference, very low certainty, from randomised trials: high risk of bias (RoB 2) in the results that carry most of the weight; one trial of 144 people found no clear difference; a small benefit can't be ruled out.

The placebo trial144 randomised · after 12 weeks

No clear difference in overall symptoms.

The evidence is very uncertain about the effect of specialized pro-resolving mediators (SPM Active) on overall symptoms in long COVID. Little or no difference · very low certainty D

  • High risk of bias (RoB 2) in the results that carry most of the weight
  • One trial of 144 people found no clear difference; a small benefit can't be ruled out
See the 1 study
  1. Effects of Specialized Pro-Resolving Mediators and Telerehabilitation on Fatigue, Dyspnea, and Quality of Life in Post‑COVID‑19 Condition: The ARACOV-02 Randomized Controlled Trial. (2026) preprint

    People in the study
    144 randomised
    Dose
    —
    Outcome
    between-group differences
    Effect
    no clear difference
    Risk of bias
    RoB 2: High
    Randomisation process
    Some concerns
    Deviations from intended interventions
    Low
    Missing outcome data
    High
    Measurement of the outcome
    Low
    Selection of the reported result
    Some concerns

Side effects

No study of this treatment alone reported side effects we could read.

Doses studied

What researchers used, as the papers print it; not a recommendation.

  1. 1Start

    3000 mg at the start

  2. 2Top dose

    Most often 3000 mg (2 of 2 studies)

All papers

  1. Effects of Specialized Pro-Resolving Mediators and Telerehabilitation on Fatigue, Dyspnea, and Quality of Life in Post‑COVID‑19 Condition: The ARACOV-02 Randomized Controlled Trial.2026 · placebo trial · 144 randomised · preprint
    Summary

    This triple-blind randomized controlled trial enrolled 144 people with Post-COVID-19 Condition (PCC). Participants were randomized 1:1 to receive either an SPM-enriched marine oil supplement or placebo; both groups also received a 12-week asynchronous telerehabilitation program delivered via the HEFORA platform. The primary outcome was health-related quality of life (EQ-5D-5L). Secondary outcomes included fatigue (FSS), dyspnea (mMRC), respiratory muscle strength (MIP/MEP), functional capacity (6MWT), and limb strength (30-s STST, 30-s ACT). Analyses followed an intention-to-treat approach. After 12 weeks, the trial found no statistically significant between-group differences (p > .05). Both groups showed significant within-group improvements. In the nutritional group, quality of life increased, fatigue decreased, and functional capacity improved (+ 37.82 m in 6MWT; p < .001); strength and respiratory pressures also increased significantly. Similar improvements were observed in the placebo group, except for dyspnea. Exploratory adherence-stratified analyses showed larger improvements among participants with higher adherence. Side effects were not reported in the available text. The authors state that the SPM-enriched supplement did not show superiority over placebo.

  2. Pro-Resolving Inflammatory Effects of a Marine Oil Enriched in Specialized Pro-Resolving Mediators (SPMs) Supplement and Its Implication in Patients with Post-COVID Syndrome (PCS).2024 · randomised trial · 53 randomised
    Summary

    This randomized, double-blind, placebo-controlled trial with four parallel supplement groups assessed a food supplement enriched in specialized pro-resolving mediators in adults with Post-COVID Syndrome. The study was conducted in 53 adult patients with PCS, selected by their treating centers. Participants received daily doses of 3000 mg (group A, 16 patients), 1500 mg (group B, 16 patients), placebo (group C, 5 patients), or 500 mg (group X, 16 patients) for 12 weeks. Group X was an independent, non-controlled low-dose group and was not blinded. The Fatigue Severity Scale (FSS) and Modified Medical Research Council (mMRC) Dyspnea Scale were assessed at baseline and weeks 4 and 12. For FSS, no significant differences were detected among the four treatment groups; a clear trend in improvement was seen in group X (500 mg). An improvement of 9% in the mean fatigue value was observed between weeks 4 and 12 for patients on 500 mg daily. For mMRC, there were no significant differences in evolution among the four groups during the study (baseline vs week 12: X-squared = 8.2496, p = 0.509; baseline vs week 4: X-squared = 7.3615, p = 0.600). A slight improvement in mMRC was observed in all groups at the end of the study. Adverse events were collected; event counts and withdrawals for harms are not reported. Numbers who worsened or stopped are not reported. The authors state limitations including the small number of recruited patients and a natural trend of improvement in PCS symptoms.

  3. Pro-resolving Inflammatory Effects of a Marine Oil Enriched in SPMs Supplement and Its Implication in Patients with a Post COVID Syndrome (PCS)2024 · randomised trial · 53 randomised
    Summary

    This randomized, double-blind, placebo-controlled trial with four parallel supplement groups enrolled 53 adult patients with Post-COVID Syndrome (PCS) at three centers. Participants received a food supplement enriched in specialized pro-resolving mediators (SPMs) at 500 mg/day (Group X, N = 16), 1500 mg/day (Group B, N = 16), or 3000 mg/day (Group A, N = 16), or placebo (Group C, N = 5), daily for 12 weeks; the paper states group X was not blinded. Fatigue Severity Scale (FSS) scores and Modified Medical Research Council (mMRC) dyspnea scores were assessed from baseline to weeks 4 and 12. All groups tend to improve the fatigue symptoms included in the FSS questionnaire, and no significant differences are detected among the four treatment groups, but a clear trend in improvement can be seen in group X, which used 500 mg of marine oil per day. An improvement of 9% in the mean value for fatigue could be observed between weeks 4 and 12 for the patients on a dosage of 500 mg daily. For dyspnea, a slight improvement can be observed for each group regarding the frequency and percentage of patients in each grade of the scale, but there were no significant differences in the evolution of the mMRC scores among the four treatment groups during the study. The paper reports no adverse event counts, side-effect results, or withdrawals for harms in this study.

  4. Longitudinal Progression of Patients with Long COVID Treated in a Post-COVID Clinic: A Cross-Sectional Survey.2024 · no comparison group · 852 in the study · 536 with outcome data
    Summary

    This cross-sectional follow-up survey asked patients with long COVID seen at a post-COVID clinic (PCoCC) about symptoms and treatments. A total of 852 patients were identified; 536 completed the survey. The mean time from COVID-19 infection to survey completion was 23.2 ± 6.4 months. There was no comparison group; patients rated symptoms at the initial clinic visit (baseline, by recall) and at follow-up on a 1-10 scale, and rated whether treatments were helpful. Surveyed treatments included low-dose naltrexone, vagal nerve stimulator, midodrine, fludrocortisone, pyridostigmine, aripiprazole, plasmapheresis, reishi mushroom and nattokinase/serrapeptase; treatment duration was not reported. Overall functioning median improved from 8 (6, 9) at baseline to 5 (3, 8) at follow-up (P < .001); fatigue improved from 8 (7,10) to 6 (3, 8) and brain fog from 8 (6, 9) to 5 (3, 8) (P < .001 for both). All individual symptoms assessed were significantly improved (P < .001). Only 4.5% (24/536) had recovered completely. Helpful ratings included low-dose naltrexone 45/77 (58%), vagal nerve stimulator 18/34 (53%), plasmapheresis 9/9 (100%), midodrine 7/17 (41%), fludrocortisone 8/17 (47%), pyridostigmine 2/3 (67%), aripiprazole 8/17 (47%), reishi mushroom 8/19 (42%) and nattokinase/serrapeptase 5/9 (56%). A minority worsened in overall function and in fatigue, myalgia and orthostasis; counts, side-effect counts, and withdrawals due to harms were not reported.

A little hope, every Sunday

New recovery stories and data-driven research on ME/CFS and long COVID. Ideas worth considering, and the evidence behind them.

Free · Unsubscribe anytime